Fibrosis-informed markers provide a decision architecture for statin allocation in intermediate-risk MASLD patients
New guidelines help doctors choose statins for liver disease patients
This guideline proposes a decision-making framework for statin therapy in the intermediate-risk stratum for patients with MASLD. It utilizes…
Doctors now have a clearer way to decide who needs statin treatment when liver health and heart risk overlap.
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement
New Liver Treatments Show Real Promise in Reversing Scarring
A systematic review and network meta-analysis of 10,119 adult patients with MASLD found pegozafermin, obeticholic acid (OCA), and resmetirom…
For the first time, doctors have clear evidence that new medications can help reverse the dangerous liver scarring caused by common fatty li…